A customer from (b)(6) alleged discrepant results generated with 2 patient samples with the cobas® liat® sars-cov-2/flu test on the cobas® liat® system.Patient 1 generated sars-cov-2 negative, flu positive and (flu a invalid).A following retest with the id-now was flu a/b negative, another retest with possibly the cobas® liat® system/id unknown the results was negative for all three targets.For patient 2 initial test was invalid, upon a first retest the result was positive for sars-cov-2, while a second retest was negative for sars-cov-2.Although requested, it could not be confirmed if the results were reported to the patient/health care provider.No harm is alleged.An investigation was conducted to evaluate the customer issue.Per the fda guidance two (2) mdrs will be filed, one per patient.An investigation was conducted to evaluate the customer issue.
|
Review of the instrument run data confirmed the alleged runs were generated potential false positive results due to abnormal baseline and photometer readings.Roche received complaints alleging invalid and/or false positive results with the cobas® sars-cov-2 & influenza a/b test for use on the cobas® liat® system for one or more targets (sars-cov-2, influenza a, influenza b).When reviewing the customer-provided data associated with the reported invalid and false positive results, abnormal pcr curves were observed.Per the on-going investigation, several potential causes for the abnormal pcr growth curves leading to invalids and false positives have been identified.These include tube leaks, abnormal pcr steps, and loose thermal sensor wiring.Overall across the installed base, these issues from product use may occur sporadically.For invalid or false positive influenza results, adverse health consequences are not likely.For invalid sars-cov-2, adverse health consequences are not likely since detectability is high and testing can be performed on alternative platforms.For erroneous positive sars-cov-2 results, there is the possibility of adverse health consequences in high risk individuals.As stated in the instructions for use, clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status.A cobas liat software update and a new cobas® sars-cov-2 & influenza a/b script to better identify errors and detect abnormal pcr curves will be made available in due course.The customer issue has been alleged on the cobas liat system, product code: occ, catalog number 07341920190 and udi (b)(4).The test used on the cobas liat system is the cobas sars-cov-2 & influenza a/b test for use on the cobas liat system ((b)(4), product code: qjr).The product catalog number for the test is 09211101190 and the udi is (b)(4).(b)(4).
|